Orforglipron (Foundayo): separating hype from phase 3 data

What did @millennialrx actually say?

The creator reviewed orforglipron, branded as Foundayo, positioning it as a new oral GLP-1 option that skips the fasting requirements of oral semaglutide (Wegovy tablet). They said Foundayo offers "seven to 12%" weight loss compared to Wegovy's "16%," called it a "non peptide small molecule," and suggested injectables will always beat oral options. They also flagged that GI side effects are still expected regardless of formulation.

To their credit, this is a reasonably accurate overview of a drug that most people haven't heard of yet. The pharmacist framing is helpful. But there are some details worth scrutinizing, particularly the weight loss numbers and the blanket statement about injectables always being superior.

Does the science back this up?

Mostly, yes, with some important caveats. Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. The non-peptide structure is a real and meaningful distinction. Because it is not a peptide, it does not get broken down in the gut the way semaglutide does, which is exactly why oral semaglutide requires fasting and specific timing.

The phase 3 ATTAIN trial data (Eli Lilly, 2024, presented at ADA) showed weight loss of approximately 7.9% to 8.7% at 36 weeks in people with type 2 diabetes. A separate phase 2 trial in adults with obesity showed up to 14.7% weight loss at 36 weeks (Wharton et al., 2023, New England Journal of Medicine). So the "seven to 12%" range the creator cited is in the right ballpark but undersells the upper end seen in obesity-only populations.

The 16% figure for oral semaglutide comes from the OASIS 1 trial (Knop et al., 2023, The Lancet), which showed 15.1% body weight reduction. The creator rounds up slightly, but it is close enough to be considered accurate.

What did they get wrong (or right)?

The biggest oversimplification is the claim that "the injectables of course, are always gonna be the best for weight loss." That was true before orforglipron data matured, but it is increasingly not a clean rule. The phase 2 orforglipron data in people with obesity showed results competitive with some injectable GLP-1 agents, though not with tirzepatide or high-dose semaglutide injectable.

What they got right: the non-peptide explanation is accurate and genuinely useful for patients confused about why one pill has strict rules and another does not. The GI side effect warning is also accurate. Clinical trial data consistently shows nausea, vomiting, and diarrhea rates for orforglipron that are comparable to injectable GLP-1 agents, particularly in the early weeks of dose escalation.

One thing the creator glossed over: Foundayo is not yet FDA-approved as of early 2025. Eli Lilly submitted for approval but the drug has not cleared regulatory review. Presenting it as a medication you can access now, without that context, could mislead viewers into thinking it is already available at their pharmacy.

What should you actually know?

If you are a patient weighing oral versus injectable GLP-1 options, the honest answer is that formulation matters less than adherence and tolerability. A drug you can actually take consistently will outperform a theoretically superior drug you skip or stop.

Orforglipron's real advantage is convenience, no fasting window, no injection, standard pill storage without refrigeration. For patients who have avoided GLP-1 therapy because of injection anxiety or the morning fasting routine, this could expand access in a meaningful way. But "easier to take" does not automatically mean "works as well for everyone."

The weight loss data also varies significantly by population. The 14.7% figure came from a non-diabetic obesity population. People with type 2 diabetes in the same drug class consistently show lower weight loss numbers, which is a pattern across all GLP-1 agents, not specific to orforglipron. Ask your provider which trial population most closely matches your own situation before drawing comparisons.

Finally, GI side effects are real and not trivial. Nausea rates in orforglipron trials ranged from 20% to 40% depending on dose, similar to semaglutide injectable. Anyone telling you the pill form will be gentler on your stomach is speculating, not reading the data.